1-甲基吡唑-4-硼酸盐酸盐 | 1026796-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基吡唑-4-硼酸盐酸盐
• 英文名称: 1-methylpyrazole-4-boronic acid hydrochloride
• 英文别名: (1-methyl-1H pyrazole-4-yl)boronic acid hydrochloride；(1-Methyl-1H-pyrazol-4-yl)boronic acid hydrochloride；(1-methylpyrazol-4-yl)boronic acid;hydrochloride
• CAS: 1026796-02-0
• 化学式: C₄H₇BN₂O₂*ClH
• 分子量: 162.384
• InChiKey: YFPLZINTZVVVJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.48
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  2-((6-chloro-[1,2,4] triazolo[4,3-b]pyridazin-3-yl)methyl)-4-(4-methoxybenzyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 、 1-甲基吡唑-4-硼酸盐酸盐 在 sodium carbonate 、 palladium dichloride 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 8.0h， 以36%的产率得到4-(4-methoxybenzyl)-2-((6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine
  参考文献：
  名称：

  신규한 트리아졸로 피리다진 유도체 및 그의 용도

  摘要：

  This is the translation of the text you provided: 该发明涉及新型三唑基吡啶衍生物或其药学上可接受的盐，以及包含它们作为有效成分的用于抑制c-Met酪氨酸激酶活性的药学组合物，以及用于预防或治疗增生性疾病的药学组合物。该发明可以通过有效抑制c-Met酪氨酸激酶的活性，用于治疗与异常激酶活性相关的过度细胞增殖和生长的各种增生性疾病，例如癌症、银屑病、类风湿关节炎、糖尿病性视网膜病变等。

  公开号：

  KR101869534B1

文献信息

• BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
  申请人：AgeneBio, Inc.

  公开号：US20180170941A1

  公开（公告）日：2018-06-21

  This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABA A receptor agonist (e.g., a α5-containing GABA A receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

  这项发明涉及苯二氮卓啉衍生物，包括含有这些苯二氮卓啉衍生物的治疗有效量的组合物，以及使用这些衍生物或组合物治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法。具体而言，它涉及在需要或有风险的受试者中治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于患有或有风险患有与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症、躁郁症、肌萎缩侧索硬化（ALS）、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症谱系障碍、脆性X综合症、瑞特综合症、强迫行为和物质成瘾。它还涉及在治疗与之相关的脑癌（包括脑肿瘤，例如髓母细胞瘤）和认知障碍的情况下，如本文所述使用α5含有的GABAA受体激动剂（例如，α5含有的GABAA受体正向变构调节剂）。
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015086635A1

  公开（公告）日：2015-06-18

  This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.

  本申请揭示了根据通用式（I）定义的化合物，其中所有变量如本文所述，这些化合物抑制Btk。本文披露的化合物可用于调节Btk的活性并治疗与过度Btk活性相关的疾病。这些化合物可用于治疗由异常B细胞激活引起的肿瘤学、自身免疫和炎症性疾病。还披露了包含通用式（I）化合物和至少一种载体、稀释剂或赋形剂的组合物。
• BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
  申请人：[en]AGENEBIO, INC.

  公开号：WO2024039886A1

  公开（公告）日：2024-02-22

  Benzazepine derivatives of Formula (I), compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders or associated with risk factors for cognitive impairment. In particular, it relates to the use of a αs-containing GABAAR agonist (e.g., a as-containing GABAAR positive allosteric modulator) in treating cognitive impairment associated with central nervous system (CNS) disorders or having a risk factor associated with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a as-containing GABAAR agonist (e.g., a as-containing GABAAR positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.
• FUNGICIDAL COMPOSITIONS
  申请人：[en]SYNGENTA CROP PROTECTION AG

  公开号：WO2024115546A1

  公开（公告）日：2024-06-06

  A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.
• WO2022/253645
  申请人：——

  公开号：——

  公开（公告）日：——